{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T02:13:42Z","timestamp":1784859222661,"version":"3.55.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.jtct.2023.05.017","type":"journal-article","created":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T02:25:32Z","timestamp":1685413532000},"page":"512.e1-512.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Low Incidence of Relapse with a Moderate Conditioning Regimen of Fludarabine, Busulfan, and Melphalan for Patients with Myeloid Malignancies: A Single-Center Analysis of 100 Patients"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0173-8459","authenticated-orcid":false,"given":"Jie-ling","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-hui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-ning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5613-1195","authenticated-orcid":false,"given":"Jiong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2023.05.017_bib0001","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/sj.bmt.1705685","article-title":"Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients","volume":"40","author":"Iravani","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.05.017_bib0002","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.bbmt.2011.02.007","article-title":"Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life","volume":"17","author":"Alatrash","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.05.017_bib0003","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3892\/mco.2016.765","article-title":"Fludarabine and busulfan as a reduced-toxicity myeloablative conditioning regimen in allogeneic hematopoietic stem cell transplantation for acute leukemia patients","volume":"4","author":"Dai","year":"2016","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.jtct.2023.05.017_bib0004","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/bmt.2015.238","article-title":"Busulfan fludarabine vs busulfan cyclophosphamide as a preparative regimen before allogeneic hematopoietic cell transplantation: systematic review and meta-analysis","volume":"51","author":"Ben-Barouch","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.05.017_bib0005","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.hemonc.2019.09.002","article-title":"Comparative effectiveness of busulfan\/cyclophosphamide versus busulfan\/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome","volume":"13","author":"Patel","year":"2020","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"10.1016\/j.jtct.2023.05.017_bib0006","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S1470-2045(15)00200-4","article-title":"Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial","volume":"16","author":"Rambaldi","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2023.05.017_bib0007","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.bbmt.2008.03.009","article-title":"Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML\/MDS","volume":"14","author":"Andersson","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.05.017_bib0008","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.bbmt.2019.12.725","article-title":"Allogeneic hemopoietic stem cell transplants in patients with acute myeloid leukemia (AML) prepared with busulfan and fludarabine (BuFlu) or thiotepa, busulfan, and fludarabine (TBF): a retrospective study","volume":"26","author":"Sora","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.05.017_bib0009","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.bbmt.2019.05.014","article-title":"Thiotepa, fludarabine, and busulfan conditioning regimen before T cell-replete haploidentical transplantation with post-transplant cyclophosphamide for acute myeloid leukemia: a bicentric experience of 100 patients","volume":"25","author":"Pagliardini","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.05.017_bib0010","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s41409-020-01074-z","article-title":"Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine\/busulfan conditioning for acute myeloid leukemia","volume":"56","author":"Bazarbachi A","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.05.017_bib0011","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.18632\/oncotarget.23273","article-title":"Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission","volume":"9","author":"Saraceni","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtct.2023.05.017_bib0012","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/cncr.30400","volume":"123","author":"Gorin","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2023.05.017_bib0013","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.bbmt.2016.06.017","article-title":"A novel reduced-toxicity myeloablative conditioning regimen using full-dose busulfan, fludarabine, and melphalan for single cord blood transplantation provides durable engraftment and remission in nonremission myeloid malignancies","volume":"22","author":"Yamamoto","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.05.017_bib0014","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s12185-018-2562-8","article-title":"Addition of melphalan to fludarabine\/busulfan (FLU\/BU4\/MEL) provides survival benefit for patients with myeloid malignancy following allogeneic bone-marrow transplantation\/peripheral blood stem-cell transplantation","volume":"109","author":"Ueda","year":"2019","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtct.2023.05.017_bib0015","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/s41409-022-01643-4","article-title":"Double alkylators based conditioning reduced the relapse rate after allogeneic peripheral blood stem cell transplantation in adult patients with myeloid malignancies: a single arm phase II study","volume":"57","author":"Jiang","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.05.017_bib0016","article-title":"Post-transplantation cyclophosphamide, tacrolimus and low-dose ATG as GVHD prophylaxis for allogeneic peripheral stem cell transplantation for adult patients with lymphoid malignancies: a single arm phase II study","volume":"8","author":"Jiang","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jtct.2023.05.017_bib0017","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.05.017_bib0018","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.05.017_bib0019","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.05.017_bib0020","article-title":"Low-dose decitabine monotherapy reverses mixed chimerism in adult patients after allogeneic hematopoietic stem cell transplantation with myeloablative conditioning regimen: a pilot phase II study","volume":"8","author":"Wang","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jtct.2023.05.017_bib0021","doi-asserted-by":"crossref","first-page":"5593","DOI":"10.1182\/blood-2011-03-343988","article-title":"Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia","volume":"118","author":"Shen","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.05.017_bib0022","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1038\/bcj.2013.31","article-title":"Prognostic significance of monitoring leukemia-associated immunophenotypes by eight-color flow cytometry in adult B-acute lymphoblastic leukemia","volume":"3","author":"Weng","year":"2013","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtct.2023.05.017_bib0023","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2307\/2530286","article-title":"A confidence interval for the median survival time","volume":"38","author":"Brookmeyer","year":"1982","journal-title":"Biometrics"},{"key":"10.1016\/j.jtct.2023.05.017_bib0024","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1541-0420.2005.00311.x","article-title":"Continuous toxicity monitoring in phase II trials in oncology","volume":"61","author":"Ivanova","year":"2005","journal-title":"Biometrics"},{"key":"10.1016\/j.jtct.2023.05.017_bib0025","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/ajh.25105","volume":"93","author":"Gorin","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2023.05.017_bib0026","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/s41409-020-0803-y","article-title":"Redefining and measuring transplant conditioning intensity in the current era: a study in acute myeloid leukemia patients","volume":"55","author":"Spyridonidis","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.05.017_bib0027","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41409-022-01908-y","article-title":"Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies","volume":"58","author":"Dul\u00e9ry","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.05.017_bib0028","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-018-0586-4","article-title":"Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT","volume":"11","author":"Ruggeri","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jtct.2023.05.017_bib0029","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S1470-2045(20)30455-1","article-title":"Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial","volume":"21","author":"Xuan","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2023.05.017_bib0030","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1200\/JCO.19.03277","article-title":"Effect of rhG-CSF combined with decitabine prophylaxis on relapse of patients with high-risk MRD-negative AML after HSCT: an open-label, multicenter, randomized Controlled trial","volume":"38","author":"Gao","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723013003?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723013003?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:09:16Z","timestamp":1763003356000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636723013003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S2666636723013003"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2023.05.017","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low Incidence of Relapse with a Moderate Conditioning Regimen of Fludarabine, Busulfan, and Melphalan for Patients with Myeloid Malignancies: A Single-Center Analysis of 100 Patients","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2023.05.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}